[
  "In 2005, Thomas Struengmann and twin Andreas sold their generic drug firm Hexal (plus a stake in Eon Labs) to Novartis for some $7 billion.",
  "They cofounded Hexal in 1986. The company launched highly successful versions of the cholesterol-lowering drug simvastatin.",
  "The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.",
  "Their venture portfolio includes Germany's BioNTech and Uruguay's Mega Pharma, initially a joint venture with Argentine billionaire Alberto Roemmers.",
  "In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann."
]